FINNENCE ▪ THE WIRE FILE
THE WIRE · № 73357
News■ Unclear/unknown
City Therapeutics is seeking up to $185 million in a U.S. IPO for its gene-silencing drugs
KINDNews
DIRECTION■ Unclear/unknown
SOURCES2
ENTITIES2
STORY SIZE2 RECORDS
FIRST SEEN2026-10-09 12:34 UTC
LAST UPDATE2026-10-09 13:08 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A gene-silencing biotech IPO adds to healthcare issuance but lacks pricing detail here.
Gene-silencing biotech seeks public listing
CATALYST TO WATCH
IPO pricing and first-day trading
MAIN RISK
Weak biotech IPO demand environment
02 THE STORY SO FAR
THE RECORD, IN ORDER.
UPDATED 2 TIMES · FIRST 2026-10-09 12:34 UTC · LAST 2026-10-09 13:08 UTC2026-10-09 12:34 UTCNewsCity Therapeutics is seeking up to $185 million in a U.S. IPO for its gene-silencing drugsCURRENT RECORD
2026-10-09 13:08 UTCNews3 Reasons Accelevation Holdings (ACCV) Looks Fully Valued As IPO Excitement Fades
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
AFFECTEDSPDR Biotech ETF · XBI
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Blood Cancer United Presents Inaugural Breakthrough Voice and Breakthrough Rising Leader Awards at First-Ever Night of Champions2026-10-09 17:37 UTC
Blood Cancer United Presents Inaugural Breakthrough Voice and Breakthrough Rising Leader Awards at First-Ever Night of Champions2026-10-09 17:37 UTC
←CORRELATIONshares Healthcare, XBI
TRex rakes in $117M IPO, while Retension reveals $45M listing2026-10-09 08:29 UTC
TRex rakes in $117M IPO, while Retension reveals $45M listing2026-10-09 08:29 UTC
←CORRELATIONshares Healthcare
Iambic sets IPO terms, seeking $150 million to advance AI-designed cancer drugs2026-10-09 11:15 UTC
Iambic sets IPO terms, seeking $150 million to advance AI-designed cancer drugs2026-10-09 11:15 UTC
←CORRELATIONshares Healthcare, XBI
TRex Bio raised $116.7 million in a U.S. IPO, pricing at the bottom of its range2026-10-09 11:54 UTC
TRex Bio raised $116.7 million in a U.S. IPO, pricing at the bottom of its range2026-10-09 11:54 UTC
←CORRELATIONshares Healthcare
New Phase 3 trial: Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2) — Viking Therapeutics, Inc.2026-10-09 12:00 UTC
New Phase 3 trial: Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2) — Viking Therapeutics, Inc.2026-10-09 12:00 UTC
←CORRELATIONshares Healthcare
New Phase 3 trial: A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma — Pfizer2026-10-09 12:00 UTC
New Phase 3 trial: A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma — Pfizer2026-10-09 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.